Washington, DC 10/4/10—DNA sequencer developer Pacific Biosciences has updated its IPO filing with the SEC, stating that it plans to offer 12,500,000 shares of common stock at a price of $15–$17 per share. The company expects proceeds of $182.5 million. Of this amount, $60–$70 million would be used for applications of SMRT technologies, $40–$60 million would be used for working capital, $20–$30 million would be used to fund planned capital expenditures and $40–$60 million would go toward other general corporate purposes.